Home Cart 0 Sign in  
X

[ CAS No. 5736-88-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 5736-88-9
Chemical Structure| 5736-88-9
Chemical Structure| 5736-88-9
Structure of 5736-88-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 5736-88-9 ]

Related Doc. of [ 5736-88-9 ]

Alternatived Products of [ 5736-88-9 ]

Product Details of [ 5736-88-9 ]

CAS No. :5736-88-9 MDL No. :MFCD00003389
Formula : C11H14O2 Boiling Point : -
Linear Structure Formula :- InChI Key :XHWMNHADTZZHGI-UHFFFAOYSA-N
M.W : 178.23 Pubchem ID :79813
Synonyms :

Calculated chemistry of [ 5736-88-9 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 13
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.36
Num. rotatable bonds : 5
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 52.74
TPSA : 26.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.46 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.33
Log Po/w (XLOGP3) : 2.72
Log Po/w (WLOGP) : 2.68
Log Po/w (MLOGP) : 2.03
Log Po/w (SILICOS-IT) : 3.03
Consensus Log Po/w : 2.56

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.67
Solubility : 0.381 mg/ml ; 0.00214 mol/l
Class : Soluble
Log S (Ali) : -2.93
Solubility : 0.211 mg/ml ; 0.00119 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.69
Solubility : 0.0367 mg/ml ; 0.000206 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.33

Safety of [ 5736-88-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 5736-88-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 5736-88-9 ]
  • Downstream synthetic route of [ 5736-88-9 ]

[ 5736-88-9 ] Synthesis Path-Upstream   1~9

  • 1
  • [ 109-65-9 ]
  • [ 123-08-0 ]
  • [ 5736-88-9 ]
YieldReaction ConditionsOperation in experiment
95% With potassium carbonate In N,N-dimethyl-formamide at 70℃; for 20 h; Inert atmosphere In a 100 mL roundbottomed flask equipped with a reflux condenser and a magneticstirring bar were dissolved 4-hydroxybenzaldehyde (35 g,287 mmol) and 1-bromobutane (30.92 mL, 287 mmol) in DMF(750 mL). The mixture then was stirred under nitrogen for 20 min.Anhydrous potassium carbonate (118.83 g, 860 mmol) was thenadded and the mixture was stirred and heated at 70 °C under nitrogen.After 20 h, the reaction was allowed to cool to room temperature,treated with excess water, and extracted with ethylacetate. The combined organic extracts were then washed withwater several times and dried over anhydrous sodium sulfate,filtered. The crude productwas purified by chromatography (PE/EA,20/1) yielding a brown oil. Yield: 95percent; 1H NMR (500 MHz, CDCl3) δH(ppm): 9.89 (s, 1H), 7.84 (d, J = 8.8 Hz, 2H), 7.00 (d, J = 8.6 Hz, 2H),4.06 (t, J = 6.3 Hz, 2H), 1.79-1.85 (m, 2H), 1.49-1.57 (m, 2H), 1.01 (t,J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δC (ppm): 190.7, 164.2,131.9, 129.8, 114.7, 68.1, 31.0, 19.1, 13.7; ESI-MS: m/z 179.2 ([M+H+]);The following alkoxy benzaldehyde derivatives 4b-h were synthesizedin a similar method.
85.4%
Stage #1: With potassium carbonate In N,N-dimethyl-formamide for 1 h; Reflux
Stage #2: at 35℃; for 12 h; Reflux
P-hydroxybenzaldehyde (2.44 g, 20 mmol), potassium carbonate (4.15 g, 30 mmol) was dissolved in 50 ml DMF solution.After heating at reflux for 1 h, cool down to 35°C.Was slowly added n-bromobutane (20mmol, 2.72g), after stirring for 10min, heated under reflux for 12h.After cooling to room temperature, the solvent was removed by rotary evaporation, extracted with dichloromethane and water, and dried over anhydrous sodium sulfate.The solvent was removed by rotary evaporation, and 3.04 g of a yellow oily liquid was purified using petroleum ether and ethyl acetate (1:1 by volume).That is, a compound having a structure represented by formula (II). Its yield was determined to be 85.4percent.
80% With potassium hydroxide In ethanol for 72 h; Reflux General procedure: These compounds were prepared according to the Williamson synthesis of ethers by a known method [22-24]. 4-hydroxybenzaldehyde (8.72 g, 71.5 mmol) was added to a solution of potassium hydroxide (4 g) in ethanol (60 mL). The mixture was treated with n-alkyl halide(71.5 mmol) (methyl iodide was used in the preparation of A1, while n-alkylbromide used inthe preparation of A1-A13) and heated under reflux. The reaction was monitored by thin-layerchromatography (TLC) using chloroform as eluent, and the optimal time of each reaction was determined. The ethanol was evaporated and the residue was dissolved in diethyl ether. The ethereal was washed with an aqueous solution of potassium hydroxide (10percent) followed by water until a pH = 7 was obtained. The organic layer was dried over sodium sulfate anhydrous and evaporated to give the desired product. The details of the reaction conditions for the preparation of each compound are described in Table 1.
73%
Stage #1: With sodium ethanolate In ethanol at 70℃; for 0.333333 h;
Stage #2: at 70℃; for 48 h;
General procedure: 4-Hydroxybenzaldehyde (244 mg, 2 mmol) was added to a solution of 46 mg (2 mmol) of sodium ethoxide in 12 mL of ethanol and stirred until completely consumed. Solution was kept under reflux (70 °C) with magnetic stirring for 20 min. The corresponding alkylation agent (n-alkyl bromide, 2 mmol) was added to the system and the temperature was maintained at 70 °C with stirring for 48 h. Compounds 2a-d were isolated by solvent extraction (ethyl acetate/water, 3:1) and then purified by distillation. Compound 2e was fussily purified by flash chromatography in silica gel (hexane/ethyl acetate; 95:05, Rf 0.4).Compound 2a (73percent yield); IR (NaCl, cm-1): ν 2985, 2935, 2738, 1692, 1260, 1163, 1040, 836; 1H NMR (250 MHz, CDCl3, TMS) δ (ppm): 9.87 (s, 1H), 7.82 (d, 2H, J = 8.9 Hz), 6.98 (d, 2H, J = 8.6 Hz), 4.12 (q, 2H, J = 7.0 Hz), 1.45 (t, 3H, J = 7.0 Hz); EI-MS, m/z 150 [M]+, 121 [HO-C6H4-CO]+, 93 [HO-C6H4]+. Compound 2b (75percent yield); IR (NaCl, cm-1): ν 2967, 2876, 2734, 1692, 1602, 1261, 1160, 834; 1H NMR (250 MHz, CDCl3, TMS) δ (ppm): 9.88 (s, 1H), 7.82 (d, 2H, J = 8.8 Hz), 6.99 (d, 2H, J = 8.8 Hz), 4.00 (t, 2H, J = 6.5 Hz), 1.85 (h, 2H, J = 7.3 Hz), 1.05 (t, 3H, J = 7.5 Hz);EI-MS, m/z 164 [M]+, 121 [HO-C6H4-CO]+, 93 [HO-C6H4]+. Compound 2c (73percent yield); IR (NaCl, cm-1): ν 2964, 2872, 2733, 1692, 1600, 1260, 1158, 828; 1H NMR (250 MHz, CDCl3, TMS) δ (ppm): 9.87 (s, 1H), 7.82 (d, 2H, J = 8.8 Hz), 6.99 (d, 2H, J = 8.7 Hz), 4.04 (t, 2H, J = 6.5 Hz), 1.80 (p, 2H, J = 6.9 Hz), 1.50 (h, 2H, J = 7.5 Hz), 0.99 (t, 3H, J = 7.3 Hz); EI-HRMS, calculated for C11H14O2m/z 178.0994, found: m/z 178.0898 [M]+, 121.0211 [HO-C6H4-CO]+ (calcd 121.0290), 93.0286 [HO-C6H4]+ (calcd 93.0340). Compound 2d (66percent yield); IR (NaCl, cm-1): ν 2931, 2856, 2741, 1697, 1600, 1254, 1156, 832; 1H NMR (250 MHz, CDCl3, TMS) δ (ppm): 9.87 (s, 1H), 7.83 (d, 2H, J = 8.8 Hz), 6.99 (d, 2H, J = 8.7 Hz), 4.03 (t, 2H, J = 6.5 Hz), 1.81 (p, 2H), 1.29-152 (m, 10H), 0.89 (t, 3H, J = 6.6 Hz); EI-MS, m/z 234 [M]+, 121 [HO-C6H4-CO]+, 93 [HO-C6H4]+. Compound 2e (isolated as a white solid, mp 44 °C, in 73percent yield); IR (KBr, cm-1): ν 2913, 2852, 2730, 1691, 1603, 1255, 1174, 837; 1H NMR (250 MHz, CDCl3, TMS) δ (ppm): 9.88 (s, 1H), 7.82 (d, 2H, J = 8.8 Hz), 6.99 (d, 2H, J = 8.8 Hz), 4.03 (t, 2H, J = 6.5 Hz), 1.81 (p, 2H, J = 6.7 Hz), 1.26-1.49 (m, 26H), 0.88 (t, 3H, J = 6.9 Hz); EI-HRMS, calculated for C23H38O2m/z 346.2872, found: m/z 346.2749 [M]+, 121.0077 [HO-C6H4-CO]+ (calcd 121.0290).
70%
Stage #1: With potassium carbonate; potassium iodide In acetonitrile at 20℃;
Stage #2: at 81℃;
General procedure: In a 50 ml two-necked round-bottomed flask provided with a magnetic stirrer and condenser, a mixture of 4-hydroxybenzaldehyde 3b (3 g, 24.6 mmol) and potassium carbonate (1.57 g, 15.9 mmol, 1.5 equiv) in dry acetonitrile (20 ml) was stirred at room temperature for 30 min. To this suspension, a solution of benzylbromide (3.08 ml, 25.83 mmol, 1.05 equiv) in 10 ml of acetonirile was added dropwise during 30 min. The resulting mixture was heated at 81 °C over a period of 96 h under vigorous magnetic stirring. Then, the reaction was allowed to cool down to room temperature and the insoluble salt (KBr) was filtered off and the filtrate was concentrated in a rotary evaporator under reduced pressure. The crude residue was dried under vacuum (10−2 Torr) for 1 h. The 4-benzyloxybenzaldehyde 3e (92percent yield) was used without further purification.

Reference: [1] Journal of the American Chemical Society, 2014, vol. 136, # 46, p. 16399 - 16410
[2] Journal of the American Chemical Society, 2010, vol. 132, # 39, p. 13675 - 13683
[3] European Journal of Medicinal Chemistry, 2017, vol. 130, p. 286 - 307
[4] Synthetic Communications, 2001, vol. 31, # 21, p. 3323 - 3328
[5] Patent: CN107556333, 2018, A, . Location in patent: Paragraph 0076-0079
[6] Journal of the Chemical Society, Dalton Transactions, 2000, # 9, p. 1437 - 1445
[7] Molecular Crystals and Liquid Crystals (1969-1991), 1988, vol. 154, p. 267 - 276
[8] Molecular Crystals and Liquid Crystals (1969-1991), 1988, vol. 154, p. 277 - 288
[9] Tetrahedron Letters, 2004, vol. 45, # 48, p. 8825 - 8829
[10] Russian Journal of Organic Chemistry, 2008, vol. 44, # 5, p. 657 - 670
[11] Molecular Crystals and Liquid Crystals, 2017, vol. 648, # 1, p. 114 - 129
[12] Journal of Medicinal Chemistry, 1981, vol. 24, # 5, p. 535 - 544
[13] Green Chemistry, 2016, vol. 18, # 9, p. 2726 - 2735
[14] Carbohydrate Research, 2012, vol. 353, p. 69 - 78
[15] European Journal of Medicinal Chemistry, 2012, vol. 58, p. 581 - 590
[16] Chemical Communications, 2015, vol. 51, # 16, p. 3403 - 3406
[17] Journal of Organic Chemistry, 2001, vol. 66, # 9, p. 2966 - 2977
[18] Journal of the American Chemical Society, 1948, vol. 70, p. 255
[19] Bulletin de la Societe Chimique de France, 1975, p. 1175 - 1178
[20] Chimica Therapeutica, 1967, vol. 2, p. 39 - 48
[21] Synthetic Communications, 1988, vol. 18, # 11, p. 1241 - 1246
[22] Journal of the American Chemical Society, 1984, vol. 106, # 11, p. 3344 - 3353
[23] Journal of the Chemical Society, Chemical Communications, 1992, # 5, p. 410 - 411
[24] Molecular Crystals and Liquid Crystals Science and Technology, Section A: Molecular Crystals and Liquid Crystals, 2000, vol. 350, p. 151 - 159
[25] Molecular Crystals and Liquid Crystals Science and Technology, Section A: Molecular Crystals and Liquid Crystals, 1994, vol. 241, p. 69 - 76
[26] Journal of Materials Chemistry, 1997, vol. 7, # 3, p. 429 - 433
[27] Journal of the Indian Chemical Society, 1996, vol. 73, # 10, p. 507 - 511
[28] Molecular Crystals and Liquid Crystals, 2003, vol. 393, p. 41 - 48
[29] Molecular Crystals and Liquid Crystals, 2006, vol. 451, # 1, p. 127 - 138
[30] Russian Journal of General Chemistry, 2005, vol. 75, # 7, p. 1113 - 1124
[31] Journal of Medicinal Chemistry, 2007, vol. 50, # 13, p. 3077 - 3085
[32] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2007, vol. 46, # 6, p. 1020 - 1024
[33] Patent: US2009/82403, 2009, A1, . Location in patent: Page/Page column 119
[34] Chemical and Pharmaceutical Bulletin, 2010, vol. 58, # 5, p. 752 - 754
[35] Patent: US2007/105904, 2007, A1, . Location in patent: Page/Page column 120
[36] Bioorganic and Medicinal Chemistry, 2011, vol. 19, # 11, p. 3361 - 3366
[37] Molecules, 2011, vol. 16, # 9, p. 7789 - 7802
[38] Molecular Crystals and Liquid Crystals, 2012, vol. 562, p. 98 - 113
[39] Molecular Crystals and Liquid Crystals, 2013, vol. 575, # 1, p. 64 - 76
[40] Molecular Crystals and Liquid Crystals, 2017, vol. 643, # 1, p. 106 - 115
[41] RSC Advances, 2014, vol. 4, # 49, p. 25940 - 25947
[42] Letters in Drug Design and Discovery, 2015, vol. 12, # 5, p. 430 - 438
[43] Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2016, vol. 152, p. 318 - 326
[44] Molecular Crystals and Liquid Crystals, 2015, vol. 616, # 1, p. 46 - 54
[45] Molecular Crystals and Liquid Crystals, 2016, vol. 625, # 1, p. 11 - 19
[46] Molecular Crystals and Liquid Crystals, 2016, vol. 633, # 1, p. 54 - 62
[47] Molecular Crystals and Liquid Crystals, 2016, vol. 633, # 1, p. 80 - 90
[48] Molecular Crystals and Liquid Crystals, 2016, vol. 634, # 1, p. 50 - 57
[49] Molecular Crystals and Liquid Crystals, 2016, vol. 637, # 1, p. 19 - 27
[50] Molecular Crystals and Liquid Crystals, 2016, vol. 638, # 1, p. 27 - 34
[51] Molecular Crystals and Liquid Crystals, 2016, vol. 638, # 1, p. 35 - 43
[52] Molecular Crystals and Liquid Crystals, 2016, vol. 638, # 1, p. 68 - 76
[53] Molecular Crystals and Liquid Crystals, 2017, vol. 643, # 1, p. 1 - 12
[54] Molecular Crystals and Liquid Crystals, 2017, vol. 643, # 1, p. 13 - 27
[55] Molecular Crystals and Liquid Crystals, 2017, vol. 643, # 1, p. 40 - 51
[56] Molecular Crystals and Liquid Crystals, 2017, vol. 643, # 1, p. 52 - 61
[57] Molecular Crystals and Liquid Crystals, 2017, vol. 643, # 1, p. 129 - 140
[58] Molecular Crystals and Liquid Crystals, 2017, vol. 643, # 1, p. 159 - 167
[59] Molecular Crystals and Liquid Crystals, 2017, vol. 643, # 1, p. 178 - 187
[60] Molecular Crystals and Liquid Crystals, 2017, vol. 643, # 1, p. 216 - 232
[61] Molecular Crystals and Liquid Crystals, 2017, vol. 643, # 1, p. 241 - 251
[62] Molecular Crystals and Liquid Crystals, 2017, vol. 652, # 1, p. 10 - 22
[63] Molecular Crystals and Liquid Crystals, 2016, vol. 625, # 1, p. 30 - 37
[64] Molecular Crystals and Liquid Crystals, 2016, vol. 630, # 1, p. 154 - 161
[65] Dyes and Pigments, 2017, vol. 137, p. 75 - 83
[66] Molecular Crystals and Liquid Crystals, 2017, vol. 652, # 1, p. 99 - 110
[67] Molecular Crystals and Liquid Crystals, 2017, vol. 652, # 1, p. 143 - 157
[68] Molecular Crystals and Liquid Crystals, 2017, vol. 652, # 1, p. 84 - 98
[69] Molecular Crystals and Liquid Crystals, 2017, vol. 648, # 1, p. 53 - 65
  • 2
  • [ 542-69-8 ]
  • [ 123-08-0 ]
  • [ 5736-88-9 ]
Reference: [1] Archiv der Pharmazie, 2017, vol. 350, # 5,
[2] Journal fuer Praktische Chemie (Leipzig), 1940, vol. <2>155, p. 332,340
[3] Journal of the Chemical Society, 1965, vol. 65, p. 1829 - 1843
[4] J. Gen. Chem. USSR (Engl. Transl.), 1976, vol. 46, p. 2044 - 2048[5] Zhurnal Obshchei Khimii, 1976, vol. 46, p. 2125 - 2130
[6] CrystEngComm, 2016, vol. 18, # 2, p. 222 - 229
  • 3
  • [ 1122-91-4 ]
  • [ 71-36-3 ]
  • [ 5736-88-9 ]
Reference: [1] Journal of the American Chemical Society, 2010, vol. 132, # 33, p. 11592 - 11598
  • 4
  • [ 862387-21-1 ]
  • [ 4045-44-7 ]
  • [ 5736-88-9 ]
Reference: [1] Tetrahedron, 2006, vol. 62, # 15, p. 3523 - 3535
  • 5
  • [ 6214-45-5 ]
  • [ 5736-88-9 ]
Reference: [1] Journal of Organic Chemistry, 1999, vol. 64, # 16, p. 5832 - 5835
  • 6
  • [ 123-08-0 ]
  • [ 5736-88-9 ]
Reference: [1] Molecular Crystals and Liquid Crystals, 2016, vol. 638, # 1, p. 95 - 102
[2] Molecular Crystals and Liquid Crystals, 2016, vol. 637, # 1, p. 37 - 46
  • 7
  • [ 874-80-6 ]
  • [ 123-11-5 ]
  • [ 123-08-0 ]
  • [ 5736-88-9 ]
Reference: [1] Letters in Organic Chemistry, 2011, vol. 8, # 1, p. 48 - 52
  • 8
  • [ 100-97-0 ]
  • [ 40141-13-7 ]
  • [ 5736-88-9 ]
Reference: [1] Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1934, vol. 198, p. 2256
  • 9
  • [ 75-52-5 ]
  • [ 123-08-0 ]
  • [ 5736-88-9 ]
  • [ 3179-08-6 ]
  • [ 115514-08-4 ]
Reference: [1] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; 15; 16; Sheet 66/106
[2] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; Sheet 79/106
[3] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 15; 16
[4] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; 15; 16; 18; 72/106
[5] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 15; 16
[6] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; Sheet 79/106
[7] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 15; 16
[8] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; 15; 16; Sheet 68/106
[9] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; 15; 16; 70/106
[10] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; 15; 16; Sheet 71/16
[11] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 15; 16
[12] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 15; 16
[13] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; 15; 16; Sheet 76/106
[14] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; Sheet 78/106
[15] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 15; 16
[16] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; 15; 16; Sheet 67/106
[17] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; 15; 16; Sheet 69/106
[18] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; 15; 16; Sheet 74/106
[19] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 4; Sheet 78/106
[20] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 15; 16
[21] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 15; 16
[22] Patent: US2009/43134, 2009, A1, . Location in patent: Page/Page column 15; 16
[23] Chemistry - A European Journal, 2009, vol. 15, # 29, p. 7052 - 7062
Recommend Products
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 5736-88-9 ]

Aryls

Chemical Structure| 5736-85-6

[ 5736-85-6 ]

4-Propoxybenzaldehyde

Similarity: 0.98

Chemical Structure| 3722-80-3

[ 3722-80-3 ]

4,4'-(Propane-1,3-diylbis(oxy))dibenzaldehyde

Similarity: 0.95

Chemical Structure| 4397-53-9

[ 4397-53-9 ]

4-(Benzyloxy)benzaldehyde

Similarity: 0.93

Chemical Structure| 18962-07-7

[ 18962-07-7 ]

4-Isobutoxybenzaldehyde

Similarity: 0.93

Chemical Structure| 67-36-7

[ 67-36-7 ]

4-Phenoxybenzaldehyde

Similarity: 0.93

Aldehydes

Chemical Structure| 5736-85-6

[ 5736-85-6 ]

4-Propoxybenzaldehyde

Similarity: 0.98

Chemical Structure| 3722-80-3

[ 3722-80-3 ]

4,4'-(Propane-1,3-diylbis(oxy))dibenzaldehyde

Similarity: 0.95

Chemical Structure| 4397-53-9

[ 4397-53-9 ]

4-(Benzyloxy)benzaldehyde

Similarity: 0.93

Chemical Structure| 18962-07-7

[ 18962-07-7 ]

4-Isobutoxybenzaldehyde

Similarity: 0.93

Chemical Structure| 67-36-7

[ 67-36-7 ]

4-Phenoxybenzaldehyde

Similarity: 0.93

Ethers

Chemical Structure| 5736-85-6

[ 5736-85-6 ]

4-Propoxybenzaldehyde

Similarity: 0.98

Chemical Structure| 3722-80-3

[ 3722-80-3 ]

4,4'-(Propane-1,3-diylbis(oxy))dibenzaldehyde

Similarity: 0.95

Chemical Structure| 4397-53-9

[ 4397-53-9 ]

4-(Benzyloxy)benzaldehyde

Similarity: 0.93

Chemical Structure| 18962-07-7

[ 18962-07-7 ]

4-Isobutoxybenzaldehyde

Similarity: 0.93

Chemical Structure| 67-36-7

[ 67-36-7 ]

4-Phenoxybenzaldehyde

Similarity: 0.93